SuperworthLite Strategy price to book ratio LITS
Market value divided by the book value of the company's net assets, since 2025.
- Today, Oct 23, 2026
- 0.8×
- Peer median
- 1.5×
Lite Strategy's price to book ratio is 0.8× as of Oct 23, 2026.
The median for 4 large drugmakers of a similar size is 1.5×.
Price to book ratio over time
Year by year
| Year | End of year | Low | High |
|---|---|---|---|
| 2026 so far | 0.8× | 0.3× | 1.0× |
| 2025 | 0.4× | 0.4× | 5.4× |
Against its peers
Companies in Drug Manufacturers - General nearest Lite Strategy's size, closest first, today.
| Company | Price to book ratio |
|---|---|
| LITSLite Strategy | 0.8× |
| ATNMActinium Pharmaceuticals | 1.6× |
| SPROSpero Therapeutics | 1.5× |
| LFVNLifevantage | 2.2× |
| NATRNatures Sunshine Products | 1.3× |
| Peer median | 1.5× |
What the price to book ratio tells you
Market value divided by the accounting value of the company's net assets. Below 1 means the market values the business at less than what it owns on paper.
Book value misses brands, software and people, so asset-light companies always look expensive on it. Most useful for banks and industrials.
More on Lite Strategy
Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.